Z6ÈËÉú¾ÍÊDz©

ͼƬÃû³Æ

ÐÂÎÅ×ÊѶ

ÕãÒ½¶ùÔºÍŶÓ×îÐÂÑо¿³É¹û£ºÊ¯É¼¼î¼×ÓÐÍûÖÎÁÆÌÇÄò²¡Éö²¡

ÈÕÆÚ£º

2024Äê10ÔÂ26ÈÕ 08:51


½üÆÚ£¬ÓÉÕã½­´óѧҽѧԺ¸½Êô¶ùͯҽԺÉöÄÚ¿ÆÍŶÓÓëZ6ÈËÉú¾ÍÊDz©ºÏ×÷¿ªÕ¹µÄʯɼ¼î¼×ÖÎÁÆÌÇÄò²¡Éö²¡µÄ¶à×éѧ·ÖÎöÑо¿·¢±íÁË×îÐÂÑо¿½á¹û£¬Ñо¿±íÃ÷ÁËʯɼ¼î¼×ÔÚ¼õÇáÌÇÄò²¡ÓÕµ¼µÄÉöËðÉË¡¢Ö¬ÖÊ´úлÎÉÂÒºÍÑ×Ö¢·½ÃæÏÔʾ³öÓÐÏ£ÍûµÄÖÎÁƹ¦Ð§¡£¸ÃÑо¿ÒÑ·¢±íÓÚ¡¶Pharmacological Research¡·ÔÓÖ¾£¬È«ÃûΪ“Huperzine A targets Apolipoprotein E: A potential therapeutic drug for diabetic nephropathy based on omics analysis”¡£

ÔçÔÚ2020Ä꣬Õã½­´óѧҽѧԺ¸½Êô¶ùͯҽԺ¾ÍÓëZ6ÈËÉú¾ÍÊDz©ºÏ×÷¿ªÕ¹¹ýÑÎËáä强ÐÂÆ¬¶Ô¶ùͯÐÂÐ͹Ú×´²¡¶¾¸ÐȾµÄÁÆÐ§¼°°²È«ÐÔÆÀ¼ÛÑо¿¡£Èç½ñÔÙ´ÎÁªÊÖ£¬ÓÖÔÚÐµļ²²¡ÁìÓòÈ¡µÃÁËϲÈ˵ijɹû¡£

 

ʯɼ¼î¼×£º×ÔÈ»À¡ÔùµÄ¶àÃæÄÜÊÖ

ʯɼ¼î¼×(Huperzine A£¬Hup A)×÷ΪÑÇÖÞÖ²ÎïÉß×ãʯɼµÄÌáÈ¡ÎïÁÙ´²Ö÷ÒªÓÃÓÚÉñ¾­ÍËÐÐÐÔ²¡ÖÎÁÆ£¬µ«½üÄêÀ´Ñо¿·¢ÏÖÆäÔÚÌÇÄò²¡ÊÓÍøÄ¤²¡±äÖоßÓÐÏÔÖøµÄ½µÑªÌǺͿ¹Ñ××÷Óᣵ«Æä¸ü¹ã·ºµÄ±£»¤×÷Óã¬ÌرðÊǶÔÌÇÄò²¡ÁíÒ»²¢·¢Ö¢ÌÇÄò²¡Éö²¡Éö¹¦Äܵı£»¤×÷ÓÃÈÔδ±»Ñо¿¡£

 

ÌÇÄò²¡Éö²¡£ºÇÄȻDZ·üµÄ½¡¿µÉ±ÊÖ

ÌÇÄò²¡£¨DM£©×÷Ϊ³£¼û²¡¡¢¶à·¢²¡£¬ÊÇÑÏÖØÍþвÈËÀཡ¿µµÄÊÀ½çÐÔ¹«¹²ÎÀÉúÎÊÌ⡣ĿǰÔÚÊÀ½ç·¶Î§ÄÚ£¬ÌÇÄò²¡»¼²¡Âʺͻ¼²¡ÈËÊý¼±¾çÉÏÉý£¬¾Ý¹ú¼ÊÌÇÄò²¡ÁªÃË£¨IDF£©Í³¼Æ£º2021ÄêÈ«Çò³ÉÄêÌÇÄò²¡ÈËÊýÒÑ´ï5.37ÒÚ£¬½Ï2019ÄêÔö¼Ó½ü16%£¬Ô¤¼Æµ½2045ÄêÈ«ÇòÌÇÄò²¡»¼²¡×ÜÈËÊý½«´ïµ½7.83ÒÚ£»2021ÄêÈ«ÇòÒòÌÇÄò²¡ËÀÍöÈËÊý´ï670Íò¡£

½ü40¶àÄêÀ´£¬Ëæ×ÅÎÒ¹ú¾­¼Ã¸ßËÙ·¢Õ¹¡¢Éú»î·½Ê½Î÷·½»¯¡¢³ÇÊл¯ºÍÈË¿ÚÀÏÁ仯¡¢·ÊÅÖÂÊÉÏÉý£¬ÎÒ¹úÌÇÄò²¡»¼²¡ÂÊÒ²³Ê¿ìËÙÔö³¤Ç÷ÊÆ£º1980ÄêÎÒ¹ú³ÉÈËÌÇÄò²¡»¼²¡ÂÊΪ0.67%£¬2007 Äê´ï9.7%£¬2017Äê¸ü¸ß´ï 11.7%¡£ÌÇÄò²¡Ç°ÆÚµÄ±ÈÀý¸ü¸ß¡£¸üΪÑÏÖØµÄÊÇÎÒ¹úÔ¼ÓÐ50%µÄÌÇÄò²¡Î´±»Õï¶Ï£»¶øÒѽÓÊÜÖÎÁÆÕߣ¬ÌÇÄò²¡¿ØÖÆ×´¿öÒ²²»ÀíÏë¡£IDFÊý¾ÝÏÔʾ£¬½ØÖÁ2021ÄêÎÒ¹ú³ÉÈËÌÇÄò²¡ÊýÁ¿Îª1.41ÒÚ¡£ÎÒ¹úÒÑÈ»³ÉΪȫÊÀ½çÌÇÄò²¡»¼Õß×î¶àµÄ¹ú¼Ò¡£

¶øÌÇÄò²¡Éö²¡(diabetic nephropathy£¬DN)ÊÇÌÇÄò²¡×îÖØÒªÇÒ×îÑÏÖØµÄ²¢·¢Ö¢Ö®Ò»£¬·¢²¡»úÖÆ¸´ÔÓ£¬Éæ¼°Ñõ»¯Ó¦¼¤¡¢Ñ×Ö¢¡¢ÏËά»¯ºÍϸ°ûµòÍö£¬ÁÙ´²ÌØÕ÷Ϊ³ÖÐøÐÔ°×µ°°×ÄòÅÅйÔö¼Ó£¬ÉöСÇòÂ˹ýÂÊ£¨eGFR£©½øÐÐÐÔϽµ£¬×îÖÕ·¢Õ¹ÎªÖÕÄ©ÆÚÉö²¡£¨ESRD£©£¬½ìʱÉöÔ๦ÄÜ»ù±¾É¥Ê§£¬ÑݱäΪÉöË¥½ß£¬ÌåÄÚ³öÏÖ´óÁ¿¶¾ËØ»ýÐˮ¡¢µç½âÖÊ¡¢Ëá¼îʧºâ£¬ÖÂËÀÂʸߣ¬Ê®·ÖΣÏÕ¡£

¶ÔÓÚÌÇÄò²¡Éö²¡£¬Ä¿Ç°µÄÁÙ´²ÖÎÁÆÈÔÒÔÔçÆÚ¿ØÖÆÑªÌÇ¡¢ÑªÑ¹ÎªÖ÷£¬½øÐÐÖÁÍíÆÚÔòÐèÒª²ÉÓÃ͸ÎöµÈÉöÔàÌæ´úÁÆ·¨½øÐÐÖÎÁÆ¡£ÉÐÎÞÓÐЧµÄÒ©Îï¸ÉÔ¤ÊֶΡ£

 

¶à×éѧ·ÖÎö£º½Òʾʯɼ¼î¼×µÄ×÷ÓûúÖÆ

±¾´ÎÑо¿ÖУ¬Ñо¿ÈËÔ±²ÉÓÃÁËת¼×é¡¢´úл×顢΢ÉúÎï×éºÍÍøÂçÒ©ÀíѧµÈ¶à×é±ð¶àѧ¿Æ×ۺϷÖÎö·½·¨£¬Ì½¾¿ÁËʯɼ¼î¼×¶ÔÓÚÌÇÄò²¡Éö²¡µÄÖÎÁÆ×÷Óá£Ñо¿½á¹ûÏÔʾ£¬Ê¯É¼¼î¼×Äܹ»Í¨¹ýµ÷¿ØApoEµÄ±í´ï£¬Æðµ½±£»¤ÉöÔà¡¢µ÷½Ú´úл¡¢¸ÄÉÆ³¦µÀ΢ÉúÎïȺ¡¢¸ÄÉÆÑ×Ö¢µÈ×÷Ó᣸ÃÑо¿Ê×´ÎÌṩÁËʯɼ¼î¼×¶ÔDNÖÎÁÆ×÷ÓõÄÖ¤¾Ý£¬±íÃ÷ʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿ØApoE£¬³ÉΪһÖÖDZÔÚµÄÔ¤·ÀºÍÖÎÁÆDNµÄÒ©Îï¡£¾ßÌåÈçÏ£º

1.  ÉöÔà±£»¤×÷ÓãºÔÚÁÙ´²ÖУ¬Äòµ°°×ÊÇÆÀ¹ÀÉö¹¦ÄܺÍËðÉË¡¢ÌáʾÉöÔ༲²¡µÄÖØÒªÖ¸±ê¡£Ñо¿±íÃ÷£¬ÔÚÐÛÐÔSD´óÊó¸øÒ©Ê¯É¼¼î¼×ºó£¬Óë¶ÔÕÕµÄδʹÓÃʯɼ¼î¼×µÄDN´óÊóÏà±È£¬Ê¹ÓÃÁËʯɼ¼î¼×µÄDN´óÊóÄòµ°°×£¨uALB£©Ë®Æ½³öÏÖ½µµÍ£¬²¢ÇÒÆäÉöÔàÖ¸Êý£¨kidney index£©¡¢Ñª¼¡ôû£¨SCr£©¡¢ÄòËØµª£¨BUN£©Ë®Æ½½ÔÓиÄÉÆ¡££¨ÈçÏÂͼ£©

£¨×¢£ºNCΪÕý³£´óÊó£»DNΪ»¼DN´óÊó£»DN+Hup AΪʹÓÃÊÇʯɼ¼î¼×µÄDN´óÊó¡££©

 

185ce18e-c079-40c8-89f1-4e828029efec133de0a8-3301-440e-ac45-5635cd28484e

 

ÁíÍ⣬´óÊóÉöСÇò£¨Glomerulus£©ºÍÉöС¹Ü£¨Renal tubule£©µÄ½á¹¹ËðÉËÔÚʯɼ¼î¼×ÖÎÁÆÏÂÒ²ÓÐËù¼õÇᣬά³ÖÕý³£ÉöСÇòÂ˹ý¹¦ÄÜËù±ØÐèµÄÉö²¡µ°°×£¨Nephrin£©ºÍ×ãÍ»µ°°×£¨Podocin£©µÄµ°°×ÖÊˮƽÔÚʯɼ¼î¼×¸øÒ©ºóÒ²ÏÔÖø»ØÉý¡£

¶ÔÕÕδÓÃÒ©µÄDN´óÊó£¬Ê¹ÓÃʯɼ¼î¼×ºóµÄ´óÊóÉöÔ๦ÄÜÖ¸±êÒÔ¼°½á¹¹ËðÉËÔÚʹÓÃʯɼ¼î¼×ºó»ù±¾¶¼ÓÐËù¸ÄÉÆ¡£Òò´Ë¿ÉÒԵóö£¬Ê¯É¼¼î¼×´æÔÚ×ŶÔÉöÔàµÄ±£»¤×÷Óá£

2.  »ùÒò±í´ïÓ°Ï죺ΪÁË̽Ë÷ʯɼ¼î¼×ÖÎÁÆDNµÄ·Ö×Ó»úÖÆ£¬Ñо¿¶ÔÉöÔà×éÖ¯½øÐÐÁËת¼×é²âÐòºÍ²îÒì±í´ï»ùÒò(DEG)·ÖÎö¡£½á¹ûÏÔʾ£¬ÔÚDN×éÖÐÏÔÖøÉϵ÷µÄApoEºÍApoC 2ÔÚʯɼ¼î¼×ÖÎÁƺóÏÔÖø½µµÍ¡£

3.  ´úлÎïµ÷½Ú£ºÑо¿Í¨¹ýÖ÷³É·Ö·ÖÎö£¨PCA£©ºÍÆ«×îС¶þ³ËÅбð·ÖÎö£¨PLS-DA£©À´Ñо¿ÉöÔà´úл±ä»¯·¢ÏÖ£¬NC×éºÍDN×éµÄÑùÆ·¾ßÓÐÏÔ×Å·ÖÉ¢ÐÔ£¬¶øDN+Hup AµÄ·Ö²¼¸ü½Ó½üNC×é¡£ÕâÒ²¾ÍÒâζ×Å£¬Ê¹ÓÃÁËʯɼ¼î¼×µÄDN´óÊóµÄÉöÔà´úлÏà±ÈÓÚδÓÃÒ©µÄDN´óÊ󣬯äÉöÔà´úл¸ü¼Ó½Ó½üÓÚÕý³£´óÊó¡£Õâ±íÃ÷ʯɼ¼î¼×ÖÎÁÆÒ»¶¨³Ì¶ÈÉϻָ´ÁËDN´óÊóµÄ´úл¡££¨ÈçÏÂͼ£©

22345db5-b057-4232-9ef9-4f9a40549f56

 

4.  ³¦µÀ΢ÉúÎïȺ¸ÄÉÆ£ºShannonÖ¸ÊýÊÇÆÀ¹À΢ÉúÎïȺÂä¶àÑùÐÔ»ò·á¸»¶ÈµÄ³£ÓÃÖ¸±ê£¬ÊýÖµÔ½¸ß±íÃ÷ȺÂäµÄ¶àÑùÐÔÔ½¸ß£¬¹ÊÑо¿ÓÃÆäÀ´ÆÀ¹Àʯɼ¼î¼×¶Ô´óÊ󳦵À΢ÉúÎïȺµÄÓ°Ïì¡£½á¹ûÏÔʾ£¬DN×éµÄShannon¶àÑùÐÔÖ¸Êý½µµÍ£¬¶øDN+Hup A×éµÄShannon¶àÑùÐÔÖ¸ÊýÔö¼Ó£¬±íÃ÷ʯɼ¼î¼×´¦Àíµ÷½ÚÁË´óÊ󳦵À΢ÉúÎïȺ¶àÑùÐÔ¡££¨ÈçÏÂͼ£©

 

00881be5-da51-45eb-b4e7-83da7a38cc61

 

 

ÁÙ´²ÒâÒ壺ApoE×÷ΪÉúÎï±êÖ¾Îï

Ϊ̽¾¿ApoEÓëDNÏà¹ØÉúÎï±êÖ¾ÎïµÄÁÙ´²Ïà¹ØÐÔ£¬Ñо¿ÄÉÈëÁË428ÀýDN»¼Õß½øÐнøÒ»²½·ÖÎö¡£

ÌÇ»¯Ñªºìµ°°×£¨HbA1c£©ÊÇѪÌÇ¿ØÖÆË®Æ½µÄÖØÒªÖ¸±ê£¬Í¨³£ÈÏΪ£¬ÌÇ»¯Ñªºìµ°°×Ũ¶È¿ÉÓÐЧµØ·´Ó³¹ýÈ¥8~12ÖÜÆ½¾ùѪÌÇˮƽ¡£Ñо¿·¢ÏÖ£¬HbA1cÓëApoE³ÊÕýÏà¹Ø£¬ÌáʾApoEµÄ±í´ïËæHbA1cˮƽµÄÉý¸ß¶øÔö¼Ó¡£

ÔÚÉö¹¦ÄÜ·½Ã棬Ôڸߵ°°×ÄòˮƽÏ£¬ApoE±í´ïÓë24 hÄòµ°°×ˮƽ³ÊÇ¿ÕýÏà¹Ø£¬±íÃ÷Ëæ×ŵ°°×ÄòˮƽµÄÉý¸ß£¬ApoE±í´ïÒ²Éý¸ß¡£

ÁíÍ⣬Ñо¿»¹·¢ÏÖ£¬ApoEÓëѪÇå°×µ°°×£¨ALB£©¡¢Ö¬ÖÊÉúÎï±êÖ¾Îï¡¢Ñ×Ö¢±êÖ¾ÎÓÈÆäÊÇCRPºÍHsCRP£©µÈ¶¼´æÔÚ½ÏΪÏÔÖøµÄÏà¹ØÐÔ¡££¨ÈçÏÂͼ£©

 

cf547a96-aa9e-43f1-af8f-88a657966c3f

 

Ñо¿»¹½øÐÐÁËApoEÇõÍÑéÖ¤£¬Çõͺóµ¼ÖÂÑ×Ö¢¼õÇᡢϸ°ûÕ³¸½Ôö¼ÓºÍϸ°û»îÐÔÉý¸ß¡£ÓëNC×éÏà±È£¬ÇõÍ×éÖÐ×ÔÊÉÌå±êÖ¾ÎïLC 3B II/LC 3B Iµ°°×±í´ïÏÔÖø½µµÍ£¬±íÃ÷ÆÏÌÑÌÇÓÕµ¼¸ü¸ßµÄ×ÔÊÉˮƽ£¬ÇõÍApoE½µµÍ×ÔÊÉˮƽ¡£

 

ÍøÂçÒ©Àíѧ£ºÑé֤ʯɼ¼î¼×µÄ¶à°Ðµã×÷ÓÃ

ͨ¹ýÍøÂçÒ©Àíѧ·ÖÎö£¬Ñо¿ÈËÔ±½øÒ»²½ÑéÖ¤ÁËʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿Ø¶à¸öÓëDNÏà¹ØµÄ»ùÒòºÍ´úл;¾¶À´·¢»Ó×÷ÓÃ, ²¢ÇÒÄܹ»Í¨¹ý¿ØÖÆÏ¸°ûµòÍö¶øÆð±£»¤×÷Óá£

 

½áÂÛ£ºÊ¯É¼¼î¼×µÄDZÁ¦ÓëδÀ´Ñо¿·½Ïò

¸ÃÑо¿Ê×´ÎÌṩÁËʯɼ¼î¼×¶ÔDNÖÎÁÆ×÷ÓõÄÖ¤¾Ý£¬±íÃ÷ʯɼ¼î¼×¿ÉÄÜͨ¹ý°ÐÏòµ÷¿ØApoE£¬³ÉΪһÖÖDZÔÚµÄÔ¤·ÀºÍÖÎÁÆDNµÄÒ©Îï¡£¾¡¹ÜÑо¿È¡µÃÁËÁîÈ˹ÄÎèµÄ½á¹û£¬µ«ÈÔÐè½øÒ»²½µÄÁÙ´²ÊÔÑéºÍ´ó¹æÄ£¶à×éѧÊý¾ÝÑéÖ¤À´ÆÀ¹Àʯɼ¼î¼×µÄÁÙ´²ÖÎÁÆÇ±ÄÜ¡£

ÌÇÄò²¡Éö²¡µÄÖÎÁÆÊÇÒ»¸ö¸´ÔӵĹý³Ì£¬µ«ÕâÏîÑо¿ÎªÎÒÃÇÌṩÁËеÄÊӽǺÍÏ£Íû¡£Ëæ×ÅÑо¿µÄÉîÈ룬ÎÒÃÇÆÚ´ýʯɼ¼î¼×Äܹ»³ÉΪÌÇÄò²¡»¼ÕßµÄи£Òô¡£ÈÃÎÒÃÇÒ»Æð¹Ø×¢ÕâÒ»ÁìÓòµÄ×îнøÕ¹£¬ÎªÌÇÄò²¡»¼Õß´øÀ´¸ü¶àµÄÏ£ÍûºÍÑ¡Ôñ¡£

 

 

Ñо¿ÎÄÏ×À´Ô´£º

f5ccbe0f-54b4-4b66-bb77-1ba428b521e9

 

 

 

ÉùÃ÷£º

1.±¾ÐÂÎÅÖ¼ÔÚ·ÖÏíѧÊõÇ°ÑØ¶¯Ì¬£¬½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿»ùÓÚѧÊõÄ¿µÄ²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£

2.Z6ÈËÉú¾ÍÊDz©ÖÆÒ©²»¶ÔÈκÎÒ©Æ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍÆ¼ö¡£

Ïà¹ØÍÆ¼ö

¡¾ÍøÕ¾µØÍ¼¡¿